Additive Effect of Pronase on the Eradication Rate of First-Line Therapy for Helicobacter pylori Infection

作者：Bang Chang Seok; Kim Yeon Soo; Park Sang Hyun; Kim Jin Bong^*; Baik Gwang Ho; Suk Ki Tae; Yoon Jai Hoon; Kim Dong Joon

来源：Gut and Liver, 2015, 9(3): 340-345.

DOI：10.5009/gnl13399

• Helicobacter pylori
• Pronase

Background/Aims: Helicobacter pylori colonizes on the apical surface of gastric surface mucosal cells and the surface mucous gel layer. Pronase is a premedication enzyme for endoscopy that can disrupt the gastric mucus layer. We evaluated the additive effects of pronase combined with standard triple therapy for H. pylori eradication. Methods: This prospective, single-blinded, randomized, controlled study was conducted between June and October 2012. A total of 116 patients with H. pylori infection were enrolled in the study (n=112 patients, excluding four patients who failed to meet the inclusion criteria) and were assigned to receive either the standard triple therapy, which consists of a proton pump inhibitor with amoxicillin and clarithromycin twice a day for 7 days (PAC), or pronase (20,000 tyrosine units) combined with the standard triple therapy twice a day for 7 days (PACE). Results: In the intention-to-treat analysis, the eradication rates of PAC versus PACE were 76.4% versus 56.1% (p=0.029). In the per-protocol analysis, the eradication rates were 87.5% versus 68.1% (p=0.027). There were no significant differences concerning adverse reactions between the two groups. Conclusions: According to the interim analysis of the trial, pronase does not have an additive effect on the eradication of H. pylori infection (ClinicalTrial.gov: NCT01645761).

• 出版日期2015-5